Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets trade near the dotted line
Tue, 21 Jul 01:30 pm

Indian indices are trading slight below the dotted line in the post noon trading session. Sectoral indices are trading mixed with stocks from the software and telecom sectors leading the gainers. However, pharma stocks are witnessing maximum selling pressure.

The BSE-Sensex is trading down 10 points (down 0.03%) and the NSE-Nifty is trading up 3 points (up 0.03%). The BSE Mid Cap index is trading down 0.5% and the BSE Small Cap index is trading down 0.4%. Commodity prices are trading on a negative note. Gold prices, per 10 grams, are trading at Rs 24,955 levels. Silver price, per kilogram, is trading at Rs 34,065 levels. Crude oil is trading at Rs 3,222 per barrel. The rupee is trading at 63.58 to the US dollar.

As per a leading financial daily, Mahindra & Mahindra (M&M) agri business division has entered into edible oil business and is planning to get into dairy and pulses retail segment as well. The company has launched the 'NuPro' brand mustard oil in the premium segment which is to be sold in the metropolis and its vicinity. It is also going to enter the other oil segments like sunflower, soya and rice bran. The company is also planning to enter the dairy business in the current fiscal year with the launch of milk and will gradually move towards the foods segment. For the last four years, revenue from the agri-business for the company has increased from Rs 0.7 bn to Rs 5.8 bn. Presently, the stock of company is trading marginally down.

Stocks in the pharma space are trading on a negative note with Sun Pharma and Cadila Healthcare leading the losses. The stock of pharma major Sun Pharma has plunged around 13.5% in today's trades. This was after the drug maker announced that its profits for FY16 will be adversely impacted owing to expenses related to its integration with Ranbaxy. As a part of this integration, the company is expecting to incur integration charges to generate long-term synergies from the aforesaid merger. The company, as a part of the process, is also looking to discontinue certain non-strategic businesses.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets trade near the dotted line". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.